Posted by Michael Wonder on 02 Feb 2024
Linvoseltamab receives EMA filing acceptance for treatment of relapsed/refractory multiple myeloma
2 February 2024 - Regeneron Pharmaceuticals today announced that the EMA has accepted for review the marketing authorisation application for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies.
A biologics license application was also submitted to the FDA in December 2023.
